Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF MEDICAL OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 69,922 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,497 · Balance 68,120 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,624 · Balance 69,744 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,750 · Balance 71,494 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,457 · Balance 73,951 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,029 · Balance 69,922 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 6,700 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 6,700 · Balance 6,700 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,371 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 2,457 · Balance 7,371 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,500 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,750 · Balance 3,500 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,624 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,624 · Balance 1,624 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,497 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 26,750 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 26,750 · Balance 26,750 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2025 Filed Aug 8, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 29,325 | $3.80 | $111,435.00 |
DisclosureSEC source: 0001415889-25-021346 · form4-08082025_040802.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 200 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-25-012541 · form4-05092025_090502.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,867 Underlying: Class A Ordinary Share · 200 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 200 | $27.00 | $5,400.00 |
DisclosureSEC source: 0001415889-25-012541 · form4-05092025_090502.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,403 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:01 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 200 | $3.80 | $760.00 |
DisclosureSEC source: 0001415889-25-012541 · form4-05092025_090502.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:47 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 8,266 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011975 · form4-05052025_080539.xml · derivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,266 Underlying: Class A Ordinary Share · 8,266 shares Expires 2035-04-30 F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F6 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:47 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 8,007 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011975 · form4-05052025_080539.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,007 Underlying: Class A Ordinary Share · 8,007 shares Expires 2035-04-30 F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F5 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:47 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 5,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011975 · form4-05052025_080539.xml · derivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,201 Underlying: Class A Ordinary Share · 5,201 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F4 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. F4 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:47 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 4,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011975 · form4-05052025_080539.xml · derivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,954 Underlying: Class A Ordinary Share · 4,954 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F3 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. F3 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010480 · form4-04092025_080424.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,497 Underlying: Class A Ordinary Share · 2,498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 734 | $20.28 | $14,885.52 |
DisclosureSEC source: 0001415889-25-010480 · form4-04092025_080424.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,403 Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,498 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010480 · form4-04092025_080424.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010007 · form4-04032025_090458.xml · derivative · entry 9 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Class A Ordinary Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010007 · form4-04032025_090458.xml · derivative · entry 8 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,248 Underlying: Class A Ordinary Share · 1,624 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 19,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010007 · form4-04032025_090458.xml · derivative · entry 7 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,657 Underlying: Class A Ordinary Share · 19,657 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee F5 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. F5 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010007 · form4-04032025_090458.xml · derivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,828 Underlying: Class A Ordinary Share · 9,828 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 39,364 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001415889-25-010007 · form4-04032025_090458.xml · derivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,364 Underlying: Class A Ordinary Share · 39,364 shares Expires 2035-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 514 | $21.77 | $11,189.78 |
DisclosureSEC source: 0001415889-25-010007 · form4-04032025_090458.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,639 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 477 | $21.77 | $10,384.29 |
DisclosureSEC source: 0001415889-25-010007 · form4-04032025_090458.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,153 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010007 · form4-04032025_090458.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,624 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010007 · form4-04032025_090458.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008612 · form4-03192025_090338.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 1,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 507 | $22.61 | $11,463.27 |
DisclosureSEC source: 0001415889-25-008612 · form4-03192025_090338.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,256 Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-008612 · form4-03192025_090338.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 475 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · derivative · entry 15 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,549 Underlying: Class A Ordinary Share · 475 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 60,217 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · derivative · entry 14 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 60,217 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 1,478 | $27.13 | $40,098.14 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 8 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,038 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $26.995 to $27.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 59,214 | $26.09 | $1,544,893.26 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 7 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,516 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $25.88 to $26.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 475 | $3.80 | $1,805.00 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 60,217 | $1.86 | $112,003.62 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · derivative · entry 13 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,725 Underlying: Class A Ordinary Share · 1,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. F9 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 835 | $26.74 | $22,327.90 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,038 Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · derivative · entry 12 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,872 Underlying: Class A Ordinary Share · 1,624 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · derivative · entry 11 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,995 Underlying: Class A Ordinary Share · 2,497 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 36,350 | $0.00 Strike: $26.74 | $0.00 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · derivative · entry 10 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,350 Underlying: Class A Ordinary Share · 36,350 shares Expires 2034-08-31 F6 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · derivative · entry 9 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,000 Underlying: Class A Ordinary Share · 7,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,994 | $26.74 | $53,319.56 |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,148 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 4,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022856 · form4-09052024_120908.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 22,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001415889-24-020104 · form4-07252024_080729.xml · derivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,217 Underlying: Class A Ordinary Share · 22,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 100 | $27.87 | $2,787.00 |
DisclosureSEC source: 0001415889-24-020104 · form4-07252024_080729.xml · nonDerivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,803 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 8,446 | $27.10 | $228,886.60 |
DisclosureSEC source: 0001415889-24-020104 · form4-07252024_080729.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,903 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $26.80 and $27.75. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 7,924 | $26.36 | $208,876.64 |
DisclosureSEC source: 0001415889-24-020104 · form4-07252024_080729.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,349 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $25.80 and $26.79. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 5,530 | $25.03 | $138,415.90 |
DisclosureSEC source: 0001415889-24-020104 · form4-07252024_080729.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,273 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $24.63 and $25.62. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 22,000 | $1.86 | $40,920.00 |
DisclosureSEC source: 0001415889-24-020104 · form4-07252024_080729.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010511 · form4-04082024_090412.xml · derivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,375 Underlying: Class A Common Share · 2,497 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 733 | $17.90 | $13,120.70 |
DisclosureSEC source: 0001415889-24-010511 · form4-04082024_090412.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,803 Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,497 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010511 · form4-04082024_090412.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010511 · form4-04082024_090412.xml · derivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,872 Underlying: Class A Common Share · 7,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F5 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010511 · form4-04082024_090412.xml · derivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,600 Underlying: Class A Common Share · 5,600 shares Expires 2034-03-31 F3 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F4 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 36,350 | $0.00 Strike: $18.06 | $0.00 |
DisclosureSEC source: 0001415889-24-010511 · form4-04082024_090412.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,350 Underlying: Class A Common Shares · 36,350 shares Expires 2034-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal month installments thereafter. The vesting commencement date is April 1, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.